title: No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: a comparative analysis.
abstract: The optimal immunosuppressive regimen for simultaneous kidney pancreas transplantation (SKPT) is still not established. We conducted a study to compare the safety and efficacy of no induction versus anti-IL-2 receptor induction protocols in SKPT recipients receiving the same maintenance regimen.
  
  
  METHODS
  Sixty-three SKPT recipients were divided into two groups: no induction group (n = 42) and anti-IL-2 receptor induction group (n = 21). All patients were maintained on tacrolimus, mycophenolate mofetil, and prednisone. Primary endpoints were 1-year acute rejection incidence and patient and graft survivals.
  
  
  RESULTS
  Demographic characteristics were similar between the groups. Acute rejection incidence at 1 year was equal in both groups (28.6%). Kidney and pancreas allograft survival in the no induction group were 78.6% and 76.2%, and in the anti-IL-2R induction group, 81% and 71.4%, respectively (P = NS). Patient survival was also similar: 83.3% in the no induction versus 85.7% in the anti-IL-2R induction group. Deaths due to sepsis were higher in the anti-IL-2R induction group, albeit not significantly.
  
  
  CONCLUSIONS
  The use of a no-induction protocol in SKPT is safe and effective immunosuppression that also reduces transplantation costs.
authors.affiliation: Beneficencia Portuguesa Hospital and Albert Einstein Hospital, Rua Maestro Cardim 769, Bloco IV 01323-001 São Paulo, SP, Brazil. Luis.Becker@med.uni-heidelberg.de
authors.forename: L E
authors.initials: LE
authors.lastname: Becker
authors.forename: V A
authors.initials: VA
authors.lastname: Nogueira
authors.forename: H
authors.initials: H
authors.lastname: Abensur
authors.forename: M P
authors.initials: MP
authors.lastname: Miranda
authors.forename: T
authors.initials: T
authors.lastname: Genzini
authors.forename: J E
authors.initials: JE
authors.lastname: Romão
authors.forename: I L
authors.initials: IL
authors.lastname: Noronha
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001706:Biopsy; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000517:prevention & control; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D000077561:Daclizumab; D009173:Mycophenolic Acid; D011241:Prednisone